Treating benign prostatic hyperplasia
OwnerOlof Mikael Trollsas, John J. Stankus +1inventors
InventorsOlof Mikael Trollsas, John J. Stankus, Shahram Shawn Gholami
Life of this patent
Estimating the term…
Abstract
Minimally invasive treatment methods for benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. The applicator containing the composition is characterized by a KIR value of between 40 and 400 Centipoise per unit area.
Claims26
A method for treating Benign Prostatic Hyperplasia (BPH) in a subject in need thereof, comprising:
- using a needle syringe containing a composition comprising a cytotoxic or cytostatic drug, a bioabsorbable copolymer, and a water soluble solvent capable of dissolving the drug and copolymer;
- and
- dispensing a total volume of the composition into a prostate to produce an efficacious outcome for treating BPH, including dispensing no more than a unit volume of the composition into a prostate at a first prostate location using the needle syringe.
A method of treating Benign Prostatic Hyperplasia (BPH) in a subject in need thereof, comprising
- using an apparatus comprising a needle syringe containing a composition comprising a cytotoxic or cytostatic drug, a bioabsorbable copolymer, and a water soluble solvent capable of dissolving the drug and copolymer, wherein the composition has an absolute viscosity, P, and the needle syringe has a needle length L with inner diameter D;
- and
- dispensing a plurality of unit volumes, v, of the composition at a respective plurality of different locations in the prostate using the needle syringe;
- wherein a unit volume is from 0.05 ml to 0.2 ml;
- wherein the plurality of unit volumes is equal to a total volume for treating BPH;
- and wherein the apparatus has a KIR of between 10 to 300 or 40 to 400 and KIR is defined as
- KIR
- =
- μ
-
- L
- 2
- vD
-
- (
- 10
- -
- 6
- )
- .
A method for treating Benign Prostatic Hyperplasia (BPH) in a subject in need thereof, comprising:
- using a needle syringe containing a composition comprising a cytotoxic or cytostatic drug, and a bioabsorbable copolymer;
- and
- dispensing a total volume of the composition into a prostate to produce an efficacious outcome for treating BPH, including dispensing no more than a unit volume of the composition into a prostate at a first prostate location using the needle syringe.
Dependencies are inferred from the claim text.